Compare · CI vs PSNL
CI vs PSNL
Side-by-side comparison of The Cigna Group (CI) and Personalis Inc. (PSNL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and PSNL operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $76.52B, about 45.1x PSNL ($1.70B).
- PSNL has been more active in the news (9 items in the past 4 weeks vs 5 for CI).
- CI has more recent analyst coverage (25 ratings vs 16 for PSNL).
- Company
- The Cigna Group
- Personalis Inc.
- Price
- $302.33+1.11%
- $15.65-1.70%
- Market cap
- $76.52B
- $1.70B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 5
- 9
- Recent ratings
- 25
- 16
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Personalis Inc.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.
Latest CI
- SEC Form 8-K filed by The Cigna Group
- The Cigna Group's Third Quarter 2026 Earnings Release Details
- Cigna Healthcare Introduces Health Sense To Connect Guidance, Benefits and Clinical Support Around Each Person, Improving Affordability and Outcomes
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- The Cigna Group Hosts 2026 Investor Day; Introduces "Lead to One" to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities
- Is Volunteering Good for Your Health? New Research From The Cigna Group Finds a Strong Connection
- Evercore ISI initiated coverage on The Cigna Group with a new price target
- The Cigna Group to Host Investor Day on September 30
- Officer Neville Everett sold $175,259 worth of shares (617 units at $284.05) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 5,053 units (SEC Form 4)
- Officer Evanko Brian C was granted 3,113 shares, increasing direct ownership by 8% to 41,030 units (SEC Form 4)
Latest PSNL
- SEC Form 425 filed by Personalis Inc.
- SEC Form 8-K filed by Personalis Inc.
- Personalis downgraded by BTIG Research
- Amendment: SEC Form SC 13E3/A filed by Personalis Inc.
- SEC Form CT ORDER filed by Personalis Inc.
- CFO AND COO Tachibana Aaron sold $47,541 worth of shares (2,931 units at $16.22), decreasing direct ownership by 1% to 195,902 units (SEC Form 4) (for withholding tax)
- President and CMO Chen Richard sold $64,848 worth of shares (3,998 units at $16.22), decreasing direct ownership by 2% to 169,882 units (SEC Form 4) to satisfy withholding obligation
- SVP and Chief Legal Officer Moore Stephen Michael sold $33,543 worth of shares (2,068 units at $16.22), decreasing direct ownership by 2% to 90,257 units (SEC Form 4) to satisfy withholding tax
- Chief Executive Officer Hall Christopher M sold $120,985 worth of shares (7,459 units at $16.22), decreasing direct ownership by 3% to 228,527 units (SEC Form 4) (withholding obligation)
- SEC Form SC 13E3 filed by Personalis Inc.